Study of MT-4561 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (such as head and neck, lung, breast, or other types listed) that has not responded to at least one prior treatment, and no standard options are left, or you cannot tolerate or refuse further standard therapies.
- You are 18 years or older.
- You have at least one measurable tumor (can be seen on scans).
- You are in good enough health to be up and about (ECOG score 0 or 1).
- Your liver, kidney, and bone marrow function are adequate based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug called MTX-531 in people with certain advanced cancers that have not responded to standard treatments. The study aims to see if the drug shrinks tumors or slows their growth, and to find the best dose.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a new drug called HSK46256 for people with advanced solid tumors that have not responded to standard treatments. The drug may target cancer cells with certain genetic changes, and the study aims to find the best dose and see how well it works.
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.